News

Quotient Sciences Wins Multiple Categories in 2023 CDMO Leadership Awards

Quotient Sciences is a multi-category award winner of the 2023 CDMO Leadership Awards. Now in its 12th year, the CDMO Leadership Awards recognizes superior performance by contract development and manufacturing organizations (CDMO's) across multiple categories, as voted by customers.

Dr. Dolly Jacob: Solubility & Bioavailability

Dr. Dolly Jacob, Director of Integrated Development Services at Quotient Sciences featured in Drug Development & Delivery looking at the challenges of solubility & bioavailability.

Dr. Vanessa Zann: Pharmaceutical Technology Contribution

Dr. Vanessa Zann, Senior Drug Development Consultant at Quotient Sciences featured in Pharmaceutical Technology looking at the important role of early-phase biopharmaceutics.

Quotient Sciences Contributes to Clinical Pharmacology in Drug Development article, "A Phase 1 Study of Savolitinib"

Quotient Sciences experts contribute to a recent article in the American College of Clinical Pharmacology® Clinical Pharmacology in Drug Development journal that highlights the results of an ADME study of AstraZeneca's savolitinib.

Quotient Sciences Expands Formulation Development Capabilities at Nottingham, UK

An expansion of our early-phase formulation development capabilities for oral dosage forms at our Nottingham, UK, facility builds upon our existing formulation capabilities.

Thought Leadership

Stuart McDougall: European Bioanalysis Forum Workshop Contribution

Stuart McDougall, Quotient Sciences' Principal Research Fellow of Bioanalytical Services, contributes to the European Bioanalysis Forum Workshop on the Harmonized Implementation of the ICH M10 Guideline.

Ensysce Biosciences' PF614-MPAR Enters Final Stage of Phase 1 Study

Ensysce Biosciences' PF614-MPAR, could be the industry's first overdose protection pain product, now entering a final Phase 1 study with Quotient Sciences.